Supplementary Materials

Supplementary Material for:

PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL+ human leukemia

Damian Lai, Min Chen, Jiechuang Su, Xiaohu Liu, Katharina Rothe, Kaiji Hu, Donna L. Forrest, Connie J. Eaves, Gregg B. Morin, Xiaoyan Jiang*

*Corresponding author. Email: xjiang{at}bccrc.ca

Published 7 February 2018, Sci. Transl. Med. 10, eaan8735 (2018)
DOI: 10.1126/scitranslmed.aan8735

This PDF file includes:

  • Materials and Methods
  • Fig. S1. Identification of a growth inhibitory compound CAN in AHI-1–transduced CML cells.
  • Fig. S2. Synergistic cytotoxicity in CML cells by combination of PP2A inhibitors with IM.
  • Fig. S3. Disruption of cell cycle control and abnormal formation of mitotic spindles in CML cells by PP2A inhibitors.
  • Fig. S4. Reduced phosphorylation and expression of signaling proteins in K562 cells after treatment with PP2A inhibitors and IM.
  • Fig. S5. Effects of PP2A inhibitors and IM on CD34+ NBM cells.
  • Fig. S6. Analysis of mice treated with LB100, DA, or a combination, 7 weeks after transplantation.
  • Fig. S7. Analysis of mice treated with LB100, DA, or a combination, 10 weeks after transplantation.
  • Fig. S8. Analysis of progenitor populations in the BM of BCR-ABL transgenic mice.

[Download PDF]